EU Panel Issues Negative Opinion on Zevra's Arimoclomol for Niemann-Pick Disease Type C

PUBT · 1d ago
EU Panel Issues Negative Opinion on Zevra's Arimoclomol for Niemann-Pick Disease Type C
  • The European Medicines Agency's CHMP issued a negative opinion on Zevra Therapeutics' arimoclomol application for Niemann-Pick disease type C.
  • The European Commission is expected to issue its final decision on the marketing authorization application within 67 days.
  • Eligible patients currently receiving arimoclomol will retain support through the global Expanded Access Program, subject to regulatory requirements.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zevra Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611130626PRIMZONEFULLFEED9877150) on November 13, 2026, and is solely responsible for the information contained therein.